Search Results
Found 1 results
510(k) Data Aggregation
(90 days)
VITEK 2 AST-Gram Negative Cefazolin (=32 µg/mL)
VITEK 2 AST-Gram Negative Cefazolin is designed for antimicrobial susceptibility testing of Gram-negative bacilli and is intended for use with the VITEK 2 Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents.
VITEK 2 AST-Gram Negative Cefazolin (≤1-≥32 µg/mL) is a quantitative test. Testing is indicated for Enterobacterales (from infections other than uncomplicated UTI) as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC).
VITEK 2 AST-Gram Negative Cefazolin (≤1-≥32 µg/mL) has demonstrated acceptable performance with the following organisms:
Enterobacterales (Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Klebsiella oxytoca, Citrobacter koseri)
The VITEK 2 Gram Negative Susceptibility Card is intended for use with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic Gram- negative bacilli to antimicrobial agents when used as instructed.
The principle of the VITEK® 2 AST cards is based on the microdilution minimum inhibitory concentration (MIC) technique reported by MacLowry and Marsh (1) and Gerlach (2). The VITEK® 2 AST card is essentially a miniaturized, abbreviated and automated version of the doubling dilution technique (3).
Each VITEK® 2 AST card contains 64 wells. A control well which only contains microbiological culture media is resident on all cards. The remaining wells contain premeasured portions of a specific antibiotic combined with culture media. The bacterial or yeast isolate to be tested is diluted to a standardized concentration with 0.45 – 0.5% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK® 2 System automatically fills, seals and places the card into the incubator/reader. The VITEK® 2 Compact has a manual filling, sealing and loading operation. The VITEK® 2 Systems monitor the growth of each well in the card over a defined period of time. At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.
VITEK® 2 AST-GN Cefazolin has the following concentrations in the card: 1, 2, and 8 (equivalent standard method concentration by efficacy in µg/mL).
The provided text describes the acceptance criteria and a study proving the device meets these criteria for the VITEK 2 AST-Gram Negative Cefazolin antimicrobial susceptibility testing system.
Here's a breakdown of the requested information:
1. Table of Acceptance Criteria and Reported Device Performance
Parameter | Acceptance Criteria (Generally Implied for AST Systems based on FDA Guidance) | Reported Device Performance (VITEK® 2 AST-GN Cefazolin) |
---|---|---|
Essential Agreement (EA) | Typically ≥ 90% (agreement between the MIC from the test device and the reference method, within a +/- 1 doubling dilution) | 97.5% (840/862) |
Category Agreement (CA) | Typically ≥ 90% (agreement between the interpretive category generated by the test device and the reference method) | 86.8% (748/862) |
Very Major Errors (VME) | As low as possible; specific limits usually apply (e.g., |
Ask a specific question about this device
Page 1 of 1